Journal of Gastroenterology and Hepatology最新文献

{"title":"Balancing Benefits and Risks: The Role of Tranexamic Acid in Upper Gastrointestinal Bleeding","authors":"Jinyu Wu, Yun Liao","doi":"10.1111/jgh.16941","DOIUrl":"10.1111/jgh.16941","url":null,"abstract":"","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":"40 5","pages":"1322-1323"},"PeriodicalIF":3.7,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143634071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to ‘Cirrhosis in primary practice: many patients remain potentially undiagnosed and are not receiving liver cancer surveillance’","authors":"","doi":"10.1111/jgh.16918","DOIUrl":"10.1111/jgh.16918","url":null,"abstract":"<p>\u0000 <span>Prince, D. S.</span>, <span>Hoque, S.</span>, <span>Kim, C.</span>, <span>Maher, S.</span>, <span>Miller, J.</span>, <span>Chomley, P.</span>, <span>Pritchard-Jones, J.</span>, <span>Spruce, S.</span>, <span>McGarry, N.</span>, <span>Baker, D.</span>, <span>Elix, P.</span>, <span>Liu, K.</span>, <span>Strasser, S. I.</span>, <span>Goodger, B.</span>, <span>Zekry, A.</span>, and <span>McCaughan, G. W.</span> (<span>2025</span>) <span>Cirrhosis in primary practice: many patients remain potentially undiagnosed and are not receiving liver cancer surveillance</span>. <i>Journal of Gastroenterology and Hepatology</i>, <span>40</span>: <span>250</span>–<span>257</span>.</p><p>The funding statement for this article was missing. The below funding statement has been added to the article:</p><p>Open access publishing facilitated by The University of Sydney, as part of the Wiley - The University of Sydney agreement via the Council of Australian University Librarians.</p><p>We apologize for this error.</p>","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":"40 5","pages":"1332"},"PeriodicalIF":3.7,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jgh.16918","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143624889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systemic Therapy for Advanced Gastrointestinal Stromal Tumors in 2025: Current Standard of Care and Emerging Therapeutic Strategies.","authors":"Joshua Tian Ming Hoe, Evelyn Yi Ting Wong, Timothy Kwang Yong Tay, Valerie Shiwen Yang","doi":"10.1111/jgh.16932","DOIUrl":"https://doi.org/10.1111/jgh.16932","url":null,"abstract":"","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143624892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NOTIFICATION: MiR-876-3p Regulates Cisplatin Resistance and Stem Cell-like Properties of Gastric Cancer Cells by Targeting TMED3","authors":"","doi":"10.1111/jgh.16919","DOIUrl":"10.1111/jgh.16919","url":null,"abstract":"<p><b>NOTIFICATION</b>: \u0000 <span>C. Peng</span>, <span>K. Huang</span>, <span>G. Liu</span>, <span>Y. Li</span>, and <span>C. Yu</span>, “ <span>MiR-876-3p Regulates Cisplatin Resistance and Stem Cell-like Properties of Gastric Cancer Cells by Targeting TMED3</span>,” <i>Journal of Gastroenterology and Hepatology</i> <span>34</span>, no. <span>10</span> (<span>2019</span>): <span>1711</span>–<span>1719</span>, https://doi.org/10.1111/jgh.14649.</p><p>This notification is for the above article, published online on 6 March 2019 in Wiley Online Library (wileyonlinelibrary.com), and has been issued by agreement between the journal Editor-in-Chief, Han-Mo Chiu; the Journal of Gastroenterology and Hepatology Foundation; and John Wiley &amp; Sons Australia, Ltd. This notification has been issued in response to concerns raised by third parties [<span>1</span>]. The article mentions a non-verifiable cell line identifier, “GSE-1” in relation to Figure 1C. Within the figure, the cell line identifier is spelled “GES-1”, which describes a verified cell line. As the authors could not be reached to clarify this discrepancy, the journal has decided to publish this notification to inform and alert readers.</p>","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":"40 4","pages":"1031"},"PeriodicalIF":3.7,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jgh.16919","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143615644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Linaclotide in Functional Dyspepsia and Constipation-Predominant Irritable Bowel Syndrome Overlap: A Randomized Trial","authors":"Li Cheng,&nbsp;Qianqian Wang,&nbsp;Biyu Wu,&nbsp;Xiujuan Yan,&nbsp;Ping Xu,&nbsp;Hongyi Qiu,&nbsp;Shengliang Chen","doi":"10.1111/jgh.16925","DOIUrl":"10.1111/jgh.16925","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aim</h3>\u0000 \u0000 <p>Linaclotide is effective in relieving constipation-predominant irritable bowel syndrome symptoms. However, few studies focus on the efficacy of linaclotide for overlapping symptoms of functional dyspepsia among irritable bowel syndrome patients. This study aimed to assess the efficacy of linaclotide compared with lactulose in patients with functional dyspepsia and constipation-predominant irritable bowel syndrome overlap.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Seventy-eight patient were randomized (2:1) to receive linaclotide 290 μg or lactulose 20 mL daily for 4 weeks. The primary endpoint was the overall treatment satisfaction for gastrointestinal symptom relief. The secondary endpoints included score changes in functional dyspepsia, constipation-predominant irritable bowel syndrome symptoms, and psychological status.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Seventy-one patients (47 with linaclotide and 24 with lactulose) completed the study. A higher proportion of patients receiving linaclotide reported partial or complete relief of gastrointestinal symptoms compared with patients receiving lactulose (87.2% vs. 54.2%, <i>p</i> = 0.002). Dyspeptic symptoms (postprandial fullness/early satiety and bloating) and bowel symptoms (stool frequency, consistency, straining, sensation of complete evacuation, and lower abdominal discomfort) showed greater improvement in linaclotide-treated patients than in lactulose group (<i>p</i> &lt; 0.05).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Linaclotide shows better efficacy for functional dyspepsia and constipation-predominant irritable bowel syndrome overlap compared with lactulose.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>ClinicalTrials.gov: NCT05134584</p>\u0000 </section>\u0000 </div>","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":"40 5","pages":"1119-1127"},"PeriodicalIF":3.7,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143615589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial Intelligence–Assisted Capsule Endoscopy Versus Conventional Capsule Endoscopy for Detection of Small Bowel Lesions: A Systematic Review and Meta-Analysis","authors":"Arkadeep Dhali,&nbsp;Vincent Kipkorir,&nbsp;Rick Maity,&nbsp;Bahadar S. Srichawla,&nbsp;Jyotirmoy Biswas,&nbsp;Roger B. Rathna,&nbsp;Hareesha Rishab Bharadwaj,&nbsp;Ibsen Ongidi,&nbsp;Talha Chaudhry,&nbsp;Gisore Morara,&nbsp;Maryann Waithaka,&nbsp;Clinton Rugut,&nbsp;Miheso Lemashon,&nbsp;Isaac Cheruiyot,&nbsp;Daniel Ojuka,&nbsp;Sukanta Ray,&nbsp;Gopal Krishna Dhali","doi":"10.1111/jgh.16931","DOIUrl":"10.1111/jgh.16931","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Capsule endoscopy (CE) is a valuable tool used in the diagnosis of small intestinal lesions. The study aims to systematically review the literature and provide a meta-analysis of the diagnostic accuracy, specificity, sensitivity, and negative and positive predictive values of AI-assisted &lt;span&gt;CE&lt;/span&gt; in the diagnosis of small bowel lesions in comparison to &lt;span&gt;CE&lt;/span&gt;.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Literature searches were performed through PubMed, SCOPUS, and EMBASE to identify studies eligible for inclusion. All publications up to 24 November 2024 were included. Original articles (including observational studies and randomized control trials), systematic reviews, meta-analyses, and case series reporting outcomes on AI-assisted &lt;span&gt;CE&lt;/span&gt; in the diagnosis of small bowel lesions were included. The extracted data were pooled, and a meta-analysis was performed for the appropriate variables, considering the clinical and methodological heterogeneity among the included studies. Comprehensive Meta-Analysis v4.0 (Biostat Inc.) was used for the analysis of the data.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A total of 14 studies were included in the present study. The mean age of participants across the studies was 54.3 years (SD 17.7), with 55.4% men and 44.6% women. The pooled accuracy for conventional &lt;span&gt;CE&lt;/span&gt; was 0.966 (95% CI: 0.925–0.988), whereas for AI-assisted &lt;span&gt;CE,&lt;/span&gt; it was 0.9185 (95% CI: 0.9138–0.9233). Conventional &lt;span&gt;CE&lt;/span&gt; exhibited a pooled sensitivity of 0.860 (95% CI: 0.786–0.934) compared with AI-assisted &lt;span&gt;CE&lt;/span&gt; at 0.9239 (95% CI: 0.8648–0.9870). The positive predictive value for conventional &lt;span&gt;CE&lt;/span&gt; was 0.982 (95% CI: 0.976–0.987), whereas AI-assisted &lt;span&gt;CE&lt;/span&gt; had a PPV of 0.8928 (95% CI: 0.7554–0.999). The pooled specificity for conventional &lt;span&gt;CE&lt;/span&gt; was 0.998 (95% CI: 0.996–0.999) compared with 0.5367 (95% CI: 0.5244–0.5492) for AI-assisted &lt;span&gt;CE&lt;/span&gt;. Negative predictive values were higher in AI-assisted &lt;span&gt;CE&lt;/span&gt; at 0.9425 (95% CI: 0.9389–0.9462) versus 0.760 (95% CI: 0.577–0.943) for conventional &lt;span&gt;CE&lt;/span&gt;.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;AI-assisted &lt;span&gt;CE&lt;/span&gt; displays superior diagnostic accuracy, sensitivity, and positive predictive values albeit the lower pooled specificity in comparison with conventional &lt;span&gt;CE&lt;/span&gt;. Its use would ensure accurate detection of small bowel lesions and further enhance their management.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 &lt;/di","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":"40 5","pages":"1105-1118"},"PeriodicalIF":3.7,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jgh.16931","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143624888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Overview of Predictive Biomarkers and Detection Approaches for Immunotherapy Response in GI Malignancies","authors":"Xinyu Chai,&nbsp;Yiwen Zhang,&nbsp;Zhihui Shi,&nbsp;Ruiling Yang,&nbsp;Xumin Liu,&nbsp;Yueting Zhou,&nbsp;Caiyang Li,&nbsp;Zhenhui Li","doi":"10.1111/jgh.16930","DOIUrl":"10.1111/jgh.16930","url":null,"abstract":"<p>This review provides an in-depth exploration of the evolving role of immunotherapy in gastrointestinal (GI) cancers, with a particular focus on immune checkpoint inhibitors (ICIs) and their associated predictive biomarkers. We present a detailed analysis of established biomarkers, such as PD-L1, microsatellite instability (MSI), tumor mutational burden (TMB), and the tumor microenvironment (TME), as well as emerging biomarkers, including gut microbiota and Epstein–Barr virus (EBV). The predictive value of these biomarkers in guiding clinical decision-making and optimizing immunotherapy outcomes is thoroughly discussed. Additionally, we highlight recent advancements in biomarker evaluation technologies, including next-generation sequencing (NGS), multiplex immunohistochemistry, and artificial intelligence (AI)–driven models. These technologies are instrumental in advancing precision medicine by enhancing the accuracy and efficiency of biomarker detection and facilitating personalized treatment approaches. The integration of these predictive biomarkers with advanced detection technologies has significantly improved the clinical efficacy of immunotherapy in GI cancers by addressing challenges such as tumor heterogeneity, immune evasion, and variable patient responses. By providing a deeper understanding of tumor biology and patient-specific factors, these tools offer the potential to optimize patient selection, treatment regimens, and, ultimately, clinical outcomes. This review underscores the transformative impact of combining predictive biomarkers with cutting-edge technologies, marking a significant step forward in the field of precision oncology for GI cancer treatment.</p>","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":"40 5","pages":"1059-1069"},"PeriodicalIF":3.7,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jgh.16930","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143615561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Panniculitis of the Lower Extremities Caused by Acute Deterioration of Autoimmune Pancreatitis","authors":"Soichiro Oda,&nbsp;Masaki Kuwatani,&nbsp;Shoya Shiratori,&nbsp;Hiroki Yonemura,&nbsp;Syunichiro Nozawa,&nbsp;Ryo Sugiura,&nbsp;Kazumichi Kawakubo,&nbsp;Kazuki Watanabe,&nbsp;Mika Watanabe,&nbsp;Naoya Sakamoto","doi":"10.1111/jgh.16934","DOIUrl":"10.1111/jgh.16934","url":null,"abstract":"<p>A 73-year-old female with type 1 autoimmune pancreatitis (AIP) presented with painful erythema on her lower extremities and elevated serum pancreatic enzyme levels. Her CT images revealed focal enlargement of the pancreatic tail with an increased density of the surrounding fatty tissue. Based on serum and CT findings, she was diagnosed as having acute deterioration of AIP. Skin biopsy of erythema revealed fat necrosis with ghost cells, calcification, and inflammatory infiltration, consistent with pancreatic panniculitis. Increasing the prednisolone dose to 25 mg/day promptly ameliorated her symptoms and normalized her enzyme levels.</p><p>Pancreatic panniculitis is a rare complication of pancreatitis characterized by painful subcutaneous nodules and fat necrosis. Although it has been reported in association with conditions such as pancreatic cancer and chronic pancreatitis, its occurrence in AIP has not been documented. This case highlights pancreatic panniculitis as a potential complication of AIP for the first time.</p>","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":"40 5","pages":"1042-1044"},"PeriodicalIF":3.7,"publicationDate":"2025-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jgh.16934","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Individualized Effects of Weight Gain in Adulthood on the Development of MASLD in Japanese Non-Obese Individuals","authors":"Kaiji Fukamizo,&nbsp;Yasuhiro Hagiwara,&nbsp;Takeshi Kimura,&nbsp;Yutaka Matsuyama","doi":"10.1111/jgh.16927","DOIUrl":"10.1111/jgh.16927","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>This study aimed to estimate the individualized effect of weight change since age 20 on the development of metabolic dysfunction–associated steatotic liver disease (MASLD) in Japanese non-obese individuals. We also assessed the clinical characteristics of high-risk individuals with weight gain.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>This retrospective cohort study included non-obese individuals who underwent health examinations at St. Luke's International Hospital between 2008 and 2018. We developed a counterfactual prediction model using logistic regression to predict the risk of MASLD onset within 3 years and predicted counterfactual risks for 5 weight change scenarios: (i) weight loss &lt; −3 kg, (ii) weight maintenance: ±3 kg, (iii) 3.1–6 kg gain, (iv) 6.1–9.9 kg gain, and (v) major weight gain ≥ 10 kg. Individualized effects of weight change were estimated using a risk difference scale, with variability assessed through their distributions and forest plots.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 20 886 individuals (64.4% women) were included, and 2016 (9.6%) developed MASLD within 3 years. The counterfactual prediction model showed the average risk difference for major weight gain ≥ 10 kg was 6.6% (median: 5.1%), with individual risk differences varied from 2% to 19% across individuals. Forest plot showed an increased average risk of 5% for men, abdominal obesity, dyslipidemia, hyperuricemia, and high ALT levels.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Weight change since age 20 is a significant risk factor for MASLD development in non-obese populations, but its impact varies widely among individuals. Men and individuals with abdominal obesity, dyslipidemia, hyperuricemia, and high ALT levels are particularly susceptible to the effects of weight gain.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":"40 5","pages":"1255-1262"},"PeriodicalIF":3.7,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jgh.16927","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143573139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cisplatin Promotes Hepatotoxicity by cGAS-STING Mediated Innate Immune Response","authors":"Qiongyan Tao,&nbsp;Yimin Zhou,&nbsp;Genwen Chen,&nbsp;Jianyong Sun","doi":"10.1111/jgh.16926","DOIUrl":"10.1111/jgh.16926","url":null,"abstract":"<div>\u0000 \u0000 <p>Although platinum-based chemotherapy represented by cisplatin has been widely approved for the management of diverse cancer types, its hepatotoxicity and other adverse effects impact patient prognosis, while currently, there are few effective strategies for prevention or treatment. RNA sequencing analysis indicated that the type I interferon (IFN-I) pathway was significantly upregulated in cisplatin-induced liver injury (CILI) mouse model. The cGAS-STING signaling was found to be significantly activated in vitro and CILI model in vivo. Mechanistically, cisplatin-induced DNA damage triggered the release of double-stranded DNA (dsDNA), which subsequently activated the cGAS-STING pathway. The activated pathway promoted the production of IFN-I and induced apoptosis, ultimately contributing to liver injury. Importantly, inhibition of the cGAS-STING pathway, either by enzymatic digestion of dsDNA or by genetic knockout of cGAS, effectively attenuated IFN-I production and liver injury in response to cisplatin. Overall, our results highlight the cGAS-STING-IFN-I axis as a promising therapeutic target for preventing and treating platinum-based drug-induced liver damage.</p>\u0000 </div>","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":"40 5","pages":"1283-1296"},"PeriodicalIF":3.7,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143573094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}